title: Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts.
abstract: Bone marrow stromal cells (BMSC) and osteoblasts are critical components of the microenvironment that support hematopoietic recovery following bone marrow transplantation. Aggressive chemotherapy not only affects tumor cells, but also influences additional structural and functional components of the microenvironment. Successful reconstitution of hematopoiesis following stem cell or bone marrow transplantation after aggressive chemotherapy is dependent upon components of the microenvironment maintaining their supportive function. This includes secretion of soluble factors and expression of cellular adhesion molecules that impact on development of hematopoietic cells. In the current study, we investigated the effects of chemotherapy treatment on BMSC and human osteoblast (HOB) expression of interleukin-6 (IL-6) as one regulatory factor. IL-6 is a pleiotropic cytokine which has diverse effects on hematopoietic cell development. In the current study we demonstrate that exposure of BMSC or HOB to melphalan leads to decreases in IL-6 protein expression. Decreased IL-6 protein is the most pronounced following melphalan exposure compared to several other chemotherapeutic agents tested. We also observed that melphalan decreased IL-6 mRNA in both BMSC and HOB. Finally, using a model of BMSC or HOB co-cultured with myeloma cells exposed to melphalan, we observed that IL-6 protein was also decreased, consistent with treatment of adherent cells alone. Collectively, these observations are of dual significance. First, suggesting that chemotherapy induced IL-6 deficits in the bone marrow occur which may result in defective hematopoietic support of early progenitor cells. In contrast, the decrease in IL-6 protein may be a beneficial mechanism by which melphalan acts as a valuable therapeutic agent for treatment of multiple myeloma, where IL-6 present in the bone marrow acts as a proliferative factor and contributes to disease progression. Taken together, these data emphasize the responsiveness of the microenvironment to diverse stress that is important to consider in therapeutic settings.
authors.affiliation: Cancer Cell Biology Program, West Virginia University, Morgantown, WV 26506, USA.
authors.forename: Stephanie L
authors.initials: SL
authors.lastname: Rellick
authors.forename: Debbie
authors.initials: D
authors.lastname: Piktel
authors.forename: Cheryl
authors.initials: C
authors.lastname: Walton
authors.forename: Brett
authors.initials: B
authors.lastname: Hall
authors.forename: William
authors.initials: W
authors.lastname: Petros
authors.forename: James E
authors.initials: JE
authors.lastname: Fortney
authors.forename: Marieta
authors.initials: M
authors.lastname: Gencheva
authors.forename: Jim
authors.initials: J
authors.lastname: Denvir
authors.forename: Gerald
authors.initials: G
authors.lastname: Hobbs
authors.forename: Michael
authors.initials: M
authors.lastname: Craig
authors.forename: Laura F
authors.initials: LF
authors.lastname: Gibson
mesh_terms: D001854:Bone Marrow Cells / Q000378:metabolism*; D018920:Coculture Techniques; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism*; D008558:Melphalan / Q000633:toxicity*; D010006:Osteoblasts / Q000378:metabolism*; D011110:Polymorphism, Genetic; D060888:Real-Time Polymerase Chain Reaction; D017154:Stromal Cells / Q000378:metabolism*
chemical_list: D015850:Interleukin-6; D008558:Melphalan